Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 4/20 | 0.61 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.61 |
| ▸ | HTR2A | P28223 | 1/20 | 0.61 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.61 |
| ▸ | HTR2B | P41595 | 1/20 | 0.61 |
| ▸ | KDM1A | O60341 | 8/20 | 0.60 |
| ▸ | MAOB | P27338 | 8/20 | 0.56 |
| ▸ | MAOA | P21397 | 7/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.56 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.56 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | HTR1A | P08908 | 1/20 | 0.56 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7002711 | 1.00 | HTR2C (0.61) | HTR2CSLC6A3HTR2ASLC6A4HTR2B | |
| SCHEMBL7002709 | 1.00 | HTR2C (0.61) | HTR2CSLC6A3HTR2ASLC6A4HTR2B | |
| SCHEMBL12971953 | 0.84 | KDM1A (0.51) | HTR2CSLC6A3HTR2ASLC6A4HTR2B | |
| SCHEMBL1645492 | 0.81 | HTR2C (0.50) | HTR2CSLC6A3HTR2ASLC6A4HTR2B | |
| SCHEMBL1645493 | 0.81 | HTR2C (0.50) | HTR2CSLC6A3HTR2ASLC6A4HTR2B | |
| SCHEMBL1646726 | 0.81 | HTR2C (0.50) | HTR2CSLC6A3HTR2ASLC6A4HTR2B | |
| SCHEMBL7000209 | 0.78 | KDM1A (0.48) | HTR2CSLC6A3KDM1AMAOBMAOA | |
| SCHEMBL7092952 | 0.78 | KDM1A (0.48) | HTR2CSLC6A3KDM1AMAOBMAOA | |
| SCHEMBL7000211 | 0.78 | KDM1A (0.48) | HTR2CSLC6A3KDM1AMAOBMAOA | |
| SCHEMBL14802698 | 0.77 | HTR2C (0.97) | HTR2CSLC6A3HTR2ASLC6A4HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110003212-B | A3 adenosine receptor agonists | 美国卫生和人力服务部 | 2022-12-06 | — | — | CN | disclosed |
| EP-2907802-B1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2019-08-07 | — | — | EP | disclosed |
| EP-2688568-B1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2019-06-19 | — | — | EP | disclosed |
| WO-2019006384-A1 | TREATMENT OF ANEURYSMS | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2019-01-03 | — | — | WO | disclosed |
| EP-3074398-A1 | A3 ADENOSINE RECEPTOR AGONISTS | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services (US) | 2016-10-05 | — | — | EP | disclosed |
| WO-2015080940-A1 | A3 ADENOSINE RECEPTOR AGONISTS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2015-06-04 | — | — | WO | disclosed |
| US-8299100-B2 | Potent and selective neuronal nitric oxide synthase inhibitors with improved membrane permeability | NORTHWESTERN UNIVERSITY (US) | 2012-10-30 | — | — | US | disclosed |
| US-20100190230-A1 | Potent and Selective Neuronal Nitric Oxide Synthase Inhibitors with Improved Membrane Permeability | NORTHWESTERN UNIVERSITY | 2010-07-29 | — | — | US | disclosed |
| EP-0996621-B1 | TRIAZOLO[4,5-d]PYRIMIDINE DERIVATIVES AS ANTI-THROMBOTIC AGENTS | ASTRAZENECA AB (SE) | 2003-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190230-A1 | Potent and Selective Neuronal Nitric Oxide Synthase Inhibitors with Improved Membrane Permeability | NOS1, NOS2, NOS3 | HTR2C 2168/4885SLC6A3 75/4885HTR2A 1266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.